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INTRODUCTION
Diabetic nephropathy (DN) is a serious complication of di-
abetes mellitus (DM) and a leading cause of end-stage renal 
disease (ESRD) worldwide [1]. The pathogenesis of DN is 
complex and implies interactions between different meta-
bolic and hemodynamic factors that concomitantly activate 
several growth factors such as connective tissue growth fac-
tor and profibrotic cytokines [2]. In addition, the hypoxic 
hypothesis of chronic kidney disease (CKD) had an evident 
role in the progression of renal injury. Renal hypoxia leads 
both to desired and undesired effects that in most cases 
maintain renal disease advancement through an ongoing vi-
cious circle [3]. Despite the beneficial effects of the current 
strategies for the treatment of DN, based mainly on adequate 
glycemic control, albuminuria and evolution of renal disease 
are not completely halted. Therefore, it is necessary to ex-
plore potential new renoprotective therapies.
Erythropoietin (EPO) is an acidic glycoprotein hormone 
that controls erythropoiesis and primarily, but not entirely, 
produced by renal interstitial fibroblasts [4]. Recombinant 
human EPO has been used clinically to accelerate erythro-
poiesis in anemia of CKD and to protect tissues in certain 
clinical settings [5]. Recently, much attention has been di-
rected toward tissue protective properties of EPO beyond 
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stimulating erythropoiesis [6]. Although the possible reno-
protective effect of EPO in the setting of CKD is of major 
clinical importance, previous reports have yielded conflict-
ing results; yet, while few reports have revealed its protective 
effects on chronic renal injury models [7], at least 13 others 
have failed to establish any effect [8].
Moreover, the tissue-protective effect of EPO was linked 
to the use of low-dose than that used for anemia correction. 
In an animal model of type 2 diabetes, chronic administra-
tion of long-acting erythropoiesis-stimulating agent had 
remarkable dose-dependent effects on cellular signaling 
of diabetic kidney injury; with low-dosage therapy totally 
displayed the tissue-protective effect [9]. Additionally, one-
month treatment with the low dose recombinant EPO has 
attenuated renal injury beyond its hematopoietic effect in 
streptozotocin (STZ)-induced diabetic rats [10]. Wheth-
er this tissue-protective effect of low-dose EPO could be 
maintained for longer periods without adverse effects is not 
known. So, the idea behind this study is to assess the effects 
of low-dose EPO on the evolution of DN in rat model. We 
used EPO in two schedules, in the first one we used EPO 
from the beginning of diabetes mellitus till the end of the 
study (28 weeks) as a prophylactic ‘preventive’ treatment; 
and in the other schedule we gave EPO after development of 
DN (the last 8 weeks only) as therapeutic treatment.
MATERIALS AND METHODS
Animals and experimental design
All experiments were conducted in accordance with Man-
soura University Institutional Research Board and the Guide 
to the Care and Use of Laboratory Animals (8th edition, 
2011, The National Academic Press, Washington, DC, USA). 
Fifty-seven male Sprague-Dawley rats (8 weeks old, 170–190 
g body wt) were acclimatized upon arrival for 5 days in a 
naturally controlled lab with 12h dark/light cycle and had 
free access to standard food and water. Rats were random-
ized into five groups (Fig 1) as follows – (1) Naïve control 
group (n=10): healthy rats injected only with citrate buffer; 
(2) EPO control group (n=10): healthy rats received EPO for 
28 weeks; (3) Untreated diabetic group (n=17; D-UT-28W): 
diabetic rats without treatment for 28 weeks after diabetes 
induction; (4) EPO prophylactically-treated diabetic group 
(n=10; D-EPO-28W): diabetic rats received EPO starting on 
day 2 after STZ injection and continued for 28 weeks (pro-
phylactic schedule); (5) EPO therapeutically-treated diabetic 
group (n=10; D-EPO-8W): diabetic rats received EPO start-
ing from the end of week 20 till the end of week 28 (thera-
peutic schedule). After 20 weeks, 7 rats from the untreated 
diabetic group were sacrificed and subjected for biochemical 
and histopathological examination to confirm development 
of DN while the residual 10 rats were allowed to continue to 
the end of the study. The type of EPO used is of recombinant 
human type and the dose in all schedules is 150 U/kg s.c. 
three times/week (epoetin alfa [Eprex®], Janssen-Cilag Co., 
NJ, USA). 
Every 4 weeks, plasma glucose, creatinine (Cr) and insu-
lin were measured from tail vein samples then rats were in-
dividually housed in metabolic cages to allow for 24 h urine 
collection and estimation of creatinine clearance (CrCl) and 
albuminuria. The mean blood pressure (MBP) was mea-
sured by indirect tail-cuff plethysmography (LE5001 pres-
sure meter, PanLab, Harvard Apparatus, Spain). At the end 
of the study, laparotomy was done under thiopental anesthe-
sia. Renal venous oxygen tension (vPO2) was analyzed from 
left renal vein blood samples (Rapid Point 400, Bayer). The 
kidneys were harvested to assess kidney/body wt (K/B) ratio 
and histopathological examination. Blood samples were col-
lected from the heart for estimation of hematocrit (Hct) val-
ue while the other portions of blood were centrifuged with 
EDTA for 10 minutes to separate plasma for further assays.
Induction of type 1 diabetes mellitus (T1DM)
Type 1 DM was induced in rats by single intraperitoneal 
injection of 60 mg/kg STZ (Sigma-Aldrich, St. Louis, MO, 
USA), dissolved in citrate buffer (0.05 mol/l, pH 4.5). Hyper-
glycemia was confirmed in all rats after 48 h by measuring 
blood glucose level from a tail vein sample after 6 h fasting 
Fig 1. Schematic representation of the experimental design.
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using a One Touch Basic blood glucose monitoring system. 
Animals with blood sugar of more than 250 mg/dl were con-
sidered diabetic and used for the study [11]. To avoid animal 
loss, severely diabetic rats with blood glucose level ≥500 mg/
dl were treated daily with low-dose NPH insulin at 4.1±1.4 
IU/kg s.c. to maintain body wt and prevent ketosis without 
normalizing hyperglycemia [12]. 
Blood biochemistry
Plasma glucose (BioMed Glucose L.S, Hanover, Germany), 
plasma insulin (DRG Diagnostics, Marburg, Germany), 
plasma creatinine (Cr; Diamond Diagnostics, Hanover, Ger-
many), and plasma EPO levels (Lifespan Bioscience Inc., 
WA, USA) were determined by using the appropriate assay 
kits according to the manufacturers’ protocols.
Morphologic analysis of renal tissue
For all groups, the kidneys were perfused in a retrograde 
manner through the abdominal aorta using 0.9% saline then 
10% neutral buffered formalin for in situ fixation. Paraffin 
sections of 5-μm thickness were evaluated using hematox-
ylin and eosin, periodic acid Schiff (PAS), and Masson tri-
chrome stains and examined by light microscopy by two 
independent pathologists who are blinded to the specimens 
examined. Glomerular changes developed in untreated dia-
betic rats at the 20th week after diabetes induction were in 
the form of mesangial matrix expansion, mesangial hyper-
cellularity, and segmental thickening of the glomerular base-
ment membrane (GBM). These lesions were mild (affecting 
<25% of glomerulus) and focal (affecting <50% of all glom-
eruli per kidney). So, these glomerular changes were scored 
according to their absence or presence as follows – normal 
(absence of lesions = score 0); presence of any one of the 
above-mentioned glomerular lesions (score 1); presence of 
two glomerular lesions (score 2); presence of the three glo-
merular lesions (score 3). Also, untreated diabetic rats after 
20 weeks developed mild tubulointerstitial and vascular le-
sions in the form of mild interstitial fibrosis, tubular atrophy, 
interstitial inflammation, and arteriolar hyalinosis. Because 
these lesions were mild, they were classified and scored ac-
cording to their absence (score 0) or presence (score 1).
Statistical analysis
Data were represented as mean ± SD for parametric data or 
frequency (number-percent) for histopathological scores. 
Parametric data were analyzed as appropriate by using the 
Student t-test or the one-way analysis of variance (ANOVA) 
followed by Tukey posthoc test. Qualitative data were ana-
lyzed as appropriate by using the Kruskal-Wallis H test, chi 
square “χ2” or Fischer’s exact tests. A P-value < 0.05 was con-
sidered significant.
RESULTS
Diabetic model after 20 weeks
The success rate of inducing diabetes (defined as fasting 
blood glucose of more than 250 mg/dl 48 h after STZ in-
jection) was 94% and the early mortality (within the 1st 
week after STZ injection) was 7.6% (data not shown). The 
survived rats were classified and recruited in the study. As 
compared to naïve rate, non-treated diabetic rats 20 weeks 
after diabetes induction had significant rise of blood glucose 
(P<0.001), plasma Cr (P<0.001), MBP (P<0.01), and de-
creased both CrCl (P<0.01) and plasma insulin (P<0.001), 
together with heavy albuminuria (P<0.001) and increase 
K/B ratio (P<0.001). Blood samples from the left renal vein 
had decreased vPO2 (P<0.001). Histopathological examina-
tion showed mild glomerular changes (score 1) in the form 
of focal mesangial matrix expansion, mesangial hypercellu-
larity, and patchy thickening of the GMB. Interstitial fibro-
sis, inflammation, and arteriolar hyalinosis were minimal or 
non-significant (Fisher’s exact test; Table 1 and Fig 3).
Fig 2. Effect of Erythropoietin (150 U/kg s.c. three times/week) on 
albuminuria of control and diabetic rats. Significance difference 
*P<0.001 vs. EPO prophylactically-treated diabetic rats (mean ± SD, 
one way ANOVA).
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General and biochemical characteristics after 
28 weeks
The number of animals died before completion of the 28 
weeks were as follows: 2 rats were lost from the untreated 
diabetic group (20% mortality); 3 rats were lost from the 
diabetic EPO prophylactically-treated group (30% mortali-
ty), and one rat was died in the diabetic EPO therapeutical-
ly-treated group at the 20th week before initiation of EPO 
administration (10% mortality). No rats were lost from ei-
ther the control naïve or control EPO groups. The number 
of rats survived the 28 weeks duration of the study is men-
tioned in Tables 2 and 3.
All survived diabetic rats remained hyperglycemic 
throughout the study, and EPO administration to the healthy 
control rats did not significantly affect blood glucose levels, 
kidney wt, plasma insulin or CrCl but caused significant in-
crease of both Hct % and the final MBP (P<0.001 and P<0.05 
respectively (Table 2). Untreated diabetic and 28 weeks EPO 
prophylactically-treated diabetic groups had significant hy-
perglycemia, insulinopenia, high plasma Cr, decreased CrCl, 
and increased K/B ratio as compared to naïve group (P<0.001 
for all). Diabetic rats received EPO only for the last 8 weeks 
(therapeutic schedule) had significant decrease of all these 
biomarkers as compared to both untreated diabetic and EPO 
prophylactically-treated groups. Likewise, untreated diabet-
ic rats had significant decrease of renal vPO2 compared to 
naïve rats (P<0.001). EPO administration to diabetic rats (in 
both prophylactic and therapeutic schedules) partially re-
stored renal vPO2 (P<0.001 and P<0.01 respectively). The 
restoration of renal vPO2 was significantly greater in ther-
apeutically-treated rats than prophylactically treated ones 
(P<0.01; Table 2). 
Although diabetic rats that were prophylactically-treated 
with EPO for 28 weeks had the highest final plasma EPO 
of all groups (P<0.001 for all), their Hct value remain com-
parable to naïve and non-treated diabetic rats. Contrary to 
this, EPO therapeutically-treated rats showed significantly 
lower final plasma EPO with high Hct value as compared to 
prophylactically-treated ones (P<0.001 for both). The final 
Fig 3. H&E staining of glomerular and tubular changes developed in 
untreated diabetic rats at the 20th week after diabetes induction. (A) 
Glomerular changes in the form of mesangial matrix expansion and 
hypercellularity (arrow), and segmental thickening of the glomerular 
basement membrane (arrow heads). These lesions were mild (affecting 
<25% of glomerulus) and focal (affecting <50% of all glomeruli 
per kidney). (B) Mild tubulointerstitial lesions in the form of mild 
interstitial fibrosis, tubular atrophy, interstitial inflammation, and 
hyalinosis.
Naïve (n=10) After 20 weeks (n=7)
Plasma glucose (mg/dl) 148.8 ± 17.3 560.8 ± 71.1‡
Plasma insulin (μg/l) 2.63 ± 0.23 0.22 ± 0.03‡
Table 1. Laboratory and 
histopathological characteristics of 
diabetic rat model after 20 weeks of 
diabetes induction.
Plasma Cr (mg/dl) 0.43 ± 0.03 0.74 ± 0.03‡
CrCl (ml/min) 1.65 ± 0.17 1.37 ± 0.21†
Albuminuria (μg/24h) 338 ± 70 2126 ± 155‡
Renal vPO2 (mmHg) 38.5 ± 2.7 25.2 ± 2.04‡
MBP (mmHg) 104.2 ± 4.58 112.3 ± 4.82†
Glomerular score (median: Min–Max) 0.00 (0–0) 1.00  (1–2)*
Interstitial fibrosis–tubular atrophy score (%) 0.0 (n=0/10) 42.8% (n=3/7)*
Interstitial inflammation (%) 0.0 (n=0/10) 42.8% (n=3/7)*
Arteriolar hyalinosis (%) 0.0 (n=0/10) 0.0 (n=0/10)
Data are presented as mean ± SD for biochemical parameters and as median (Min–Max) for glomerular score or percentage of lesion for intersti-
tial fibrosis-tubular atrophy, interstitial inflammation, and arteriolar hyalinosis. 
Significant difference: *P<0.05, †P<0.01, ‡P<0.001 (Student’s t-test for parametric data and Kruskal-Wallis H test, chi-square or Fisher›s exact 
tests for qualitative data).
Abbreviations: Cr = creatinine; CrCl = creatinine clearance; MBP = mean blood pressure; vPO2= venous oxygen tension.
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MBP of EPO therapeutically-treated rats was significantly 
lower than that of the EPO prophylactically-treated and EPO 
control (P<0.05 and P<0.01 respectively); however both had 
higher MBP than untreated diabetic group (P<0.001 and 
P<0.01 respectively; Table 2).
Albuminuria
Compared to both naïve and EPO control groups, all diabetic 
groups (treated and untreated) showed significant escalation 
of albuminuria starting from the 4th week and thereafter 
(Fig 2; significance marks vs. controls not shown). However, 
diabetic rats received EPO for 28 weeks (prophylactic sched-
ule) had significantly higher albuminuria starting from the 
12th week till the end of the study in comparison with oth-
er groups. Diabetic rats received EPO for the last 8 weeks 
(therapeutic schedule) had significantly less albuminuria at 
the 24th and 28th weeks as compared to both untreated and 
EPO prophylactically-treated diabetic groups (P<0.001 for 
both, Fig 2).
Renal histopathology
As shown in Fig 4, administration of EPO for 28 weeks did 
not significantly induce histopathological abnormalities in 
control rats. Untreated diabetic rats showed significant in-











K/B ratio (mg/g) 5.48 ± 0.25 5.47 ± 0.2 10.28 ± 1.17 ‡ab 11.03 ± 1.07 ‡ab 8.04± 0.63 ‡abcd
Plasma glucose (mg/dl) 148.8 ± 17.3 145.5 ± 23.7 556.9 ± 86.7 ‡ab 542.5±105.4 ‡ab 523.6±75.2 ‡ab
Plasma insulin (μg/l) 2.63 ± 0.23 2.45 ± 0.2 0.18 ± 0.10 ‡ab 0.16 ± 0.12 ‡ab 0.17 ±0.08 ‡ab
Plasma Cr (mg/dl) 0.43 ± 0.03 0.39 ± 0.03 1.04 ± 0.07 *ab 1.05 ±0.07 *ab 0.70 ±0.02 *abcd
CrCl (ml/min) 1.65 ± 0.17 1.43 ± 0.14 1.1 ± 0.10 ‡ab 1.21 ± 0.13 ‡a,*b 1.35±0.12 ‡a, †c
Albuminuria (μg/24h) 377 ± 90 410 ± 112 3286 ± 220 ‡ab 4875 ± 252 ‡ab, *c 2359 ± 214 ‡ab, *cd
Renal vPO2 (mmHg) 38.5 ± 2.7 42.6 ± 4.57 14.9 ± 2.62 ‡ab 22.2 ± 2.77 ‡ac, †b 28.4±2.85 ‡abc, †d
Plasma EPO (pg/ml) 39.7 ± 4.81 47.1 ± 5.85 43.5 ± 6.56 80.0 ± 12.4 ‡abc 46.5±4.88 ‡d
Hct (%) 45.2 ± 2.73 58.5 ± 3.69 ‡a 41.7 ± 2.88 ‡b 43.4 ± 3.11 ‡b 55.8±3.41‡acd
MBP (mmHg) 104.2 ± 4.58 118 ± 5.89 *a 97.5 ± 6.21 115.6 ± 5.26 *a, ‡c 107.5±4.86 †bc, *d
a= significance difference vs. naïve control; b = significance difference vs. EPO control group; c = significance difference vs. untreated diabetic 
(D-UT-28W) group; d = significance difference vs. EPO prophylactically-treated (D-EPO-28W) group.
Significance levels: *P<0.05; †P<0.01; ‡P<0.001 (Mean ± SD, one way ANOVA and Tukey posthoc test).
Abbreviations: D = diabetic; EPO = Erythropoietin; UT = untreated; K/B = kidney/Body wt; Cr = creatinine; CrCl = creatinine clearance; vPO2 = 
venous oxygen tension; Hct= hematocrit; MBP = mean blood pressure.











Glomerular score 5.48 ± 0.25 5.47 ± 0.2 10.28 ± 1.17 ‡ab 11.03 ± 1.07 ‡ab 8.04± 0.63 ‡abcd
Median (Min-Max) 0.00 (0 –0) 0.00 (0 –1) 1.00 (1–2) *a 2.00 (1–2) †a 0.50 (0 –1) *bc
Interstitial fibrosis - tubular 
atrophy score (%)
0.0 (n=0/10) 0.0 (n=0/10) 37.5 (n=3/8) 71.4 (n=5/7) *a 0.0 (n=0/9) *c
Interstitial inflammation (%) 0.0 (n=0/10) 0.0 (n=0/10) 37.5 (n=3/8) 100.0 (n=7/7) †a, *b 44.4 (n=4/9) *c
Arteriolar hyalinosis (%) 0.0 (n=0/10) 0.0 (n=0/10) 25.0 (n=2/8) 0.0 (n=0/7) 33.3 (n=3/9)
Data are expressed as median (Min–Max) for glomerular score and percentage of lesion for interstitial fibrosis-tubular atrophy, interstitial inflam-
mation, and arteriolar hyalinosis. 
a = significance difference vs. EPO control group; b = significance difference vs. untreated diabetic (D-UT-28W) group; c = significance difference 
vs. EPO prophylactically-treated (D-EPO-28W) group.
Significance levels: *P<0.05; †P<0.01 (Kruskal-Wallis H test for glomerular score; Fisher’s exact tests for interstitial fibrosis-tubular atrophy, inter-
stitial inflammation, and arteriolar hyalinosis scores).
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crease of glomerular changes score (P<0.05, K-W) with mild 
interstitial fibrosis, inflammation, and arteriolar hyalinosis 
as compared to naïve and EPO control groups (Table 3 and 
Fig 4C, Fisher’s exact test). EPO prophylactically-treated 
diabetic rats had significant increase in scores of glomeru-
lar changes (P<0.01), interstitial fibrosis–tubular atrophy 
(P<0.05), and interstitial inflammation (P<0.01) as com-
pared to EPO control groups. In addition, EPO prophylac-
tically-treated diabetic group showed significant picture of 
acute tubular injury and degeneration that was not included 
in DN pathological scoring system (Fig 4D). Contrary to 
this, EPO therapeutically-treated rats showed significant de-
crease in glomerular changes (P<0.05, K-W), interstitial fi-
brosis, and inflammation as compared to both untreated dia-
betic and EPO prophylactically-treated diabetic rats (P<0.05, 
chi square test; Fig 4E).
DISCUSSION
Recombinant human EPO has long been used for correction 
of anemia due to CKD since it was first synthesized in 1987 
[13]. In this study we aimed at studying the possible role of 
recombinant EPO on the progression of DN in rat model 
since the available data on this topic are not consistent and 
leave many open questions [8,14]. We used EPO in low-dose 
to dissociate its tissue protective effect from its hematopoiet-
ic one. In the first schedule we gave EPO to diabetic rats from 
the beginning of hyperglycemia till the end of the study (28 
weeks) as a possible preventive treatment of DN; and in the 
second one, we employed EPO only for the last 8 weeks (af-
ter development of DN) as a possible therapeutic treatment. 
Unexpectedly, prophylactic administration of low-dose EPO 
to diabetic rats all over 28 weeks led to marked progression 
of albuminuria which is commonly considered a good pre-
dictor for progressive nephropathy [15]. This finding was 
also associated with elevation of the final MBP and aggrava-
tion of renal histological damage. Contrary to this, adminis-
tration of EPO to diabetic rats in the last 8 weeks after the de-
velopment of DN led to some favorable effects in the form of 
deceased albuminuria, lowering of final MBP and improve-
ment of the renal histological deterioration. In addition, the 
EPO prophylactically-treated diabetic group had the highest 
mortality proportion among all experimental groups where 
3 out of 10 rats died before the end of the study while only 
one rat was died in the therapeutically-treated group during 
the first 20 weeks after diabetes induction, and before initia-
tion of EPO treatment. 
The concern that recombinant human EPO might in-
duce progressive deterioration of renal function in patients 
Fig 4. Representative glomerular (left) and tubulointerstitial (right) 
changes after 28 weeks in 5 groups of rats. (A) Control naïve rate with 
normal glomerular and tubulointerstitial architecture. (B) Control EPO 
rats without significant changes than naïve rats. (C) Diabetic untreated 
rats showing axial mesangial expansion and interstitial fibrosis with 
tubular atrophy (trichrome stain). (D) Diabetic EPO prophylactically-
treated rats (for 28 weeks) showing mesangial hypercellularity and 
interstitial inflammatory cell infiltrations (arrow head). (E) Diabetic 
EPO therapeutically-treated rats (for the last 8 weeks) showing mild 
mesangial expansion and hypercellularity with some focal interstitial 
inflammation (PAS stain).
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with CKD was previously arisen from experimental data in 
the partially nephrectomized uremic rat model where Gretz 
and co-workers reported that EPO administration to the 5/6 
nephrectomized rats caused progression of the renal deteri-
oration and increased mortality as compared to control rats 
[16]. However, such deleterious effect has not been reported 
in clinical setting where EPO is commonly used by patients 
with CKD for anemia correction [17]. In addition, we re-
ported that the final plasma EPO concentration in the pro-
phylactically-treated diabetic rats was noticeably higher than 
its level in other groups, such finding that could be attributed 
to decline of the urinary excretion of EPO as a part of the 
general picture of deteriorated nephropathy. Supporting ev-
idence of this finding also exists to denote that prolonged 
EPO administration resulted in an inhibition of the urinary 
excretion of endogenous EPO [18].
We used EPO in the same dose used by Toba and 
co-workers [10] who reported that neither blood pressure 
nor Hct was affected by the administration of EPO in a dose 
of 150 U/kg three times/week for 4 weeks. However, our re-
sults showed that 28 weeks administration of this low dose 
led to rise of blood pressure and Hct in non-diabetic rats; 
so, longer treatment duration would indeed allow EPO-side 
effects to show up and confirms other reports which indi-
cate that hypertension develops in approximately 30% of 
patients with CKD maintained on EPO therapy [19]. Mech-
anisms of this hypertension have been proposed to include 
increased blood viscosity, endothelin release, and inhibition 
of endothelial nitric oxide production [20-21]. Systemic hy-
pertension could further aggravate glomerular dysfunction 
through augmentation of renal hypoxia and aggravation of 
oxidative stress in the kidney [22]. 
The chronic hypoxia hypothesis proposed that hypoxic 
milieu precedes and triggers a fibrotic response leading to 
renal fibrosis and progression of glomerular injury [23-24]. 
Likewise, it was postulated that hypoxia-induced tubuloint-
erstitial injury may provoke interstitial fibrosis and weakness 
of peritubular capillaries that would impair the tubular and 
interstitial oxygen supply [25]. These hazards would defi-
nitely constitute a vicious circle that intensifies renal injury. 
In the present study, we measured renal vPO2 as an indi-
cator of renal tissue hypoxia and we found that, in diabetic 
rats, vPO2 was significantly lower than control rats denoting 
an increased intrarenal consumption of oxygen probably as 
a reflection of increased inrarenal oxidative stress [26]. Al-
though the administration of EPO to diabetic rats in both 
the prophylactic and therapeutic schedules has partially im-
proved renal vPO2 when compared to non-treated diabetic 
rats, but prophylactically-treated animals suffered both exag-
gerated albuminuria and worsened histological picture than 
non-treated diabetic animals, suggesting that the pathogen-
esis of DN is a multifactorial process that relies on complex 
signaling networks rather than hypoxia per se. However, in 
the therapeutically-treated rats, the improvement of vPO2 
was greater than that found in the prophylactically-treated 
ones suggesting that administration of EPO at this precise 
point might disrupt the renal hypoxia-induced endogenous 
EPO secretion cycle and possibly affect other signaling net-
works involved in the evolution of DN, consequently attenu-
ated the progression of DN.
We also found that administration of EPO for 28 weeks 
in control non-diabetic rats produced significant increase 
of Hct value. This result proves that prolonged administra-
tion of such low-dose of EPO is hematologically effective; 
however, this hematopoietic effect failed to be similarly re-
produced in diabetic rats prophylactically-treated with EPO 
for 28 weeks which showed hematological profile nearly 
similar to the untreated diabetic group. A possible explana-
tion might be the development of resistance to both exog-
enously administered and the endogenously secreted EPO 
within the hyperglycemic environment as a result of chronic 
low-grade inflammation with its impact on the hematopoi-
etic process [27] and aggravation of oxidative stress [28]. In 
support of this assumption, a number of preclinical and clin-
ical studies have reported a major role of several inflamma-
tory cytokines, adhesion molecules, and chemokines in the 
development and progression of DN [29-30]. These pro-in-
flammatory cytokines downregulate the EPO receptors’ ex-
pression on erythroid progenitors and interrupt iron recy-
cling by impeding its release from reticuloendothelial cells 
[31-32]. In addition, the oxidative stress is a critical factor in 
the etiology of diabetic complications [33] and may partic-
ipate in EPO resistance by causing lipid peroxidation of red 
cell membranes [34]. 
In conclusion, prophylactic low-dose administration of 
EPO for 28 weeks to diabetic rats led to marked progres-
sion of albuminuria and worsening of the renal histological 
changes in spite of partial improvement of renal hypoxia. 
This was joined to increased endogenous EPO secretion and 
rise of final MBP. By contrast, some benefit was obtained 
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when EPO was only given for the last 8 weeks after develop-
ment of DN as a therapeutic intervention. It is probable that 
renal hypoxia occurs at a particular time during the course 
of diabetic renal disease might be able to have adverse renal 
outcome, while the administration of EPO at this particular 
time could disrupt the renal hypoxia-induced endogenous 
EPO secretion cycle and hence prevents or slows down the 
evolution of DN. Moreover, chronic hypertension triggered 
by long-term administration of EPO could further aggra-
vate glomerular dysfunction and intrarenal oxidative stress. 
However the precise mechanism(s) of this differential effect 
of EPO in DN should be investigated in further studies in 
which precise assessment of EPO-induced renal injury on 
the molecular level may enhance some mechanistic insight. 
Likewise, whether the hyperglycemic environment inter-
frered or masked a possible renoprotective role of EPO in di-
abetic rats should be further investigated in clinical studies.
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